Objective: The aim of this study was to evaluate the clinicopathological features of uterine sarcoma in Hokkaido, Japan, between 1990 and 1999, and to identify prognostic factors of patients with such malignancies in this area and period. Methods: One hundred and six patients with histologically proven uterine sarcoma were evaluated retrospectively. Results: 93.5% of the patients with carcinosarcoma (CS) were diagnosed as having malignant disease preoperatively, while 65% of those with leiomyosarcoma (LMS) and 75% of those with endometrial stromal sarcoma (ESS) were preoperatively diagnosed as benign leiomyoma. When patients had no residual disease postoperatively, 5-year survival rates in patients with CS and LMS were 78.8 and 73.0%, respectively. ESS cases had a better prognosis (94.7% for stage I cases). In patients with early-stage sarcoma, pelvic lymphadenectomy and adjuvant chemotherapy, with or without cis-diamminedichloroplatinum, failed to show a survival benefit in both CS and LMS cases. Distant metastasis, myometrial invasion, and no residual disease at surgery were significantly associated with risk of death or recurrence in CS and LMS cases. Conclusion: Accurate preoperative diagnosis of uterine sarcoma was difficult, and no residual disease at surgery was the most important prognostic factor in patients with this disease. Postoperative adjuvant therapy had little effect on survival , especially in early-stage disease.

Keywords:
Preoperative diagnosis, Residual disease, Adjuvant therapy, Survival, Uterine sarcoma
1.
Zaloudek C, Norris HJ: Mesenchymal tumors of the uterus; in Kurman RJ (ed): Balustein’s Pathology of the Female Genital Tract, ed 4. New York, Springer, 1994, pp 487–528.
2.
Berek J, Hacker N: Practical Gynecologic Oncology, ed 3. Baltimore, Williams & Wilkins, 2000, pp 441–446.
3.
Nordal RR, Thoresen SO: Uterine sarcomas in Norway 1956–1992: Incidence, survival and mortality. Eur J Cancer 1997;33:907–911.
4.
Schwartz SM, Thomas DB: A case-control study of risk factors for sarcomas of the uterus. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer 1989;64:2487–2492.
5.
Leibsohn S, d’Ablaing G, Mishell DR Jr, Schlaerth JB: Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol 1990;162:968–976.
6.
Rose PG, Piver MS, Tsukada Y, Lau T: Patterns of metastasis in uterine sarcoma. An autopsy study. Cancer 1989;63:935–938.
7.
Wolfson AH, Wolfson DJ, Sitttler SY, et al: A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas. Gynecol Oncol 1994;52:56–62.
8.
Mayerhofer K, Obermair A, Windbichler G, Petru E, Kaider A, Hefler L, Czerwenka K, Leodolter S, Kainz C: Leiomyosarcoma of the uterus: A clinicopathologic multicenter study of 71 cases. Gynecol Oncol 1999;74:196–201.
9.
Gadducci A, Landoni F, Sartori E, Zola P, Maggino T, Lissoni A, Bazzurini L, Arisio R, Romagnolo C, Cristofani R: Uterine leiomyosarcoma: Analysis of treatment failures and survival. Gynecol Oncol 1996;62:25–32.
10.
Pautier P, Genestie C, Rey A, Morice P, Roche B, Lhomme C, Haie-Meder C, Duvillard P: Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 2000;88:1425–1431.
11.
Arrastia CD, Fruchter RG, Clark M, et al: Uterine carcinosarcomas: Incidence and trends in management and survival. Gynecol Oncol 1997;65:158–163.
12.
Silverberg SG, Major FJ, Blessing JA, Fetter B, Askin FB, Liao S-Y, Miller A: Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990;9:1–9.
13.
Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ: World Health Organization international histological classification of tumours: Histological typing of female genital tract tumours, ed 2. Springer, Berlin, 1994.
14.
Pecorelli S, Benedet JL, Creasman WT, Shepherd JH: FIGO staging of gynecologic cancer: 1994–1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet 1999;65:243–249.
15.
Sobin LH, Wittekind C: TNM classification of malignant tumours. UICC, ed 6. New York, Wiley, 2002, pp 147–151.
16.
SAS Institute Inc: SAS Procedures Guide, ed 8. Cary, SAS Institute Inc, 2000.
17.
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
18.
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977;35:1–39.
19.
Cox DR: Regression models and life tables. J R Stat Soc 1972;34:187–220.
20.
Bodner K, Boner-Adler B, Obermair A, et al: Prognostic parameters in endometrial stromal sarcoma: A clinicopathologic study in 31 patients. Gynecol Oncol 2001;81:160–165.
21.
Kvale G, Heuch I, Ursin G: Reproductive factors and risk of cancer of the uterine corpus: A prospective study. Cancer Res 1988;48:6217–6221.
22.
Kobayashi K, Sagae S, Kudo R, Saito H, Koi S, Nakamura Y: Microsatellite instability in endometrial carcinomas: Frequent replication errors in tumors of early onset and/or of poorly differentiated type. Genes Chromosomes Cancer 1995;14:128–132.
23.
Parker WH, Fu YS, Berek JS: Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994;83:414–418.
24.
Wang X, Khoo US, Xue WC, Cheung AN: Cervical and peritoneal fluid cytology of uterine sarcomas. Acta Cytol 2002;46:465–469.
25.
Goto A, Takeuchi S, Sugimura K, Maruo T: Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus. Int J Gynecol Cancer 2002;12;354–361.
26.
Umesaki N, Tanaka T, Miyama M, Kawamura N, Ogita S, Kawabe J, Okamura T, Koyama K, Ochi H: Positron emission tomography with 18F-fluorodeoxyglucose of uterine sarcoma: A comparison with magnetic resonance imaging and power Doppler imaging. Gynecol Oncol 2001;80:372–377.
27.
Covens AL, Nisker JA, Chapman WB, Allen HH: Uterine sarcoma: An analysis of 74 cases. Am J Obstet Gynecol 1987;56:370–374.
28.
Major FJ, Blessing JA, Silverberg SG, et al: Prognostic factors in early-stage uterine sarcomas. A Gynecologic Oncology Group study. Cancer 1993;71:1702–1709.
29.
Goff BA, Rice LW, Fleischhacker D, et al: Uterine leiomyosarcoma and endometrial stromal sarcoma: Lymph node metastases and sites of recurrence. Gynecol Oncol 1993;50:105–109.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.